Related Experiment Video
Updated: Feb 5, 2026

A Permanent Window for Investigating Cancer Metastasis to the Lung
Published on: July 1, 2021
miR-330-3p promotes lung cancer cells invasion, migration, and metastasis by directly targeting hSOD2b
Lianghua Shen1, Shanze Yi1, Luyuan Huang2
1Institute of Genomic Medicine, College of Pharmacy, Jinan University, Guangzhou, People's Republic of China.
Abstract:
Lung cancer is a serious threat to human health. Studies have revealed that human manganese superoxide dismutase (hSOD2) and miRNAs play an essential role in the metastasis process of lung cancer. However, the miRNAs that associated with hSOD2 and involved in metastasis, remain elusive. After databases analysis and dual luciferase reporter validation, we demonstrated that miR-330-3p expression inversely correlated with hSOD2b expression level, and that miR-330-3p directly targeted the 3'untranslated region (3'UTR) of hSOD2b. Furthermore, overexpression of miR-330-3p promoted whereas knockdown of miR-330-3p inhibited invasion/migration and the epithelial-mesenchymal transition (EMT) process of lung cancer cells in vitro. Knockdown of miR-330-3p inhibited metastasis of lung cancer cells in vivo. Moreover, miR-330-3p-mediated enhancement of invasion/migration in 95-D cells could be rescued by over-expression of hSOD2. In conclusion, we demonstrated that miR-330-3p promoted metastasis of lung cancer cells by suppressing hSOD2b expression and unveiled a new clinical application of miR-330-3p in the therapy of lung cancer.
Related Concept Videos
Cancer Cell Migration through Invadopodia
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cell Migration
Cell Migration
The Eukaryotic Promoter Region
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

